Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Yabao Pharmaceuticals Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment

BEIJING--(BUSINESS WIRE)--Yabao Pharmaceutical Co., Inc. (Shanghai Stock Exchange: 600351), a leading pharmaceutical company in China, today announced a second strategic collaboration for the treatment of diabetes with Eli Lilly and Company to co-develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule. Lilly's SGLT1 inhibitor program has completed a Phase I study in Singapore, in addition to extensive pre-clinical development. In July 2014, Lilly and Yabao also announced the co-development of Lilly's glucokinase activator (GKA), LY2608204.

Diabetes is a disease of great unmet need in China and worldwide. Inhibition of intestinal SGLT1 is a promising therapeutic approach because it acts independently of the beta cell and may therefore be effective in both early-stage and advanced diabetes. The reduction in both glucose and insulin may improve the metabolic state and potentially the health of the beta cells in the absence of body weight gain or hypoglycemia. Its complementary mechanism could be effective when used in combination with other important diabetes drugs.

Under the terms of the agreement, Yabao receives the rights to develop and commercialize the SGLT1 compound in China, while Lilly retains rights in all other markets. The parties will collaborate to determine a strategic development plan for China, and Yabao will initially be responsible to perform and fund all development. Lilly retains future buy-in options for China. Financial terms were not disclosed.

"Lilly's SGLT1 Inhibitor program is based on a mechanistic understanding and chemistry approach that has the potential to enable the development of a best-in-class agent. Yabao is again pleased to be collaborating with Lilly, a global leader in diabetes, on our second strategic collaboration, which demonstrates our joint commitment to diabetes patients in China," commented Dr. Peng Wang, President R&D, Yabao Pharmaceutical Co. "This collaboration is also another example of Yabao's continued commitment to collaborate and develop promising science in China."

About Yabao Pharmaceutical Co.

Yabao Pharmaceutical is a leading Chinese pharmaceutical company with fully-integrated development, manufacturing, and commercialization in China. Yabao is recently pursuing strategic development of innovative pharmaceuticals in addition to Yabao's well-established business in modern traditional Chinese medicines and chemical generics. Yabao has strong capabilities in clinical, regulatory, formulation and API production and meets cGMP requirements with facilities approved by the U.S. FDA and European agency. Visit http://www.yabao.com.cn for more information.

October 20, 2015

Source: http://www.businesswire.com/

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies